SQZ Biotechnologies Stock Forecast, Price & News

SQZ Biotechnologies (NYSE:SQZ) Frequently Asked Questions

Is SQZ Biotechnologies a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SQZ Biotechnologies in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SQZ Biotechnologies stock.
View analyst ratings for SQZ Biotechnologies or view top-rated stocks.

When is SQZ Biotechnologies' next earnings date?

SQZ Biotechnologies is scheduled to release its next quarterly earnings announcement on Thursday, March 17th 2022.
View our earnings forecast for SQZ Biotechnologies.

How were SQZ Biotechnologies' earnings last quarter?

SQZ Biotechnologies (NYSE:SQZ) posted its earnings results on Wednesday, November, 10th. The company reported ($0.80) EPS for the quarter, missing the Zacks' consensus estimate of ($0.56) by $0.24. SQZ Biotechnologies had a negative trailing twelve-month return on equity of 51.18% and a negative net margin of 432.38%.
View SQZ Biotechnologies' earnings history.

Who are SQZ Biotechnologies' key executives?

SQZ Biotechnologies' management team includes the following people:

• Dr. Armon R. Sharei, Co-Founder, Pres, CEO & Director (Age 34, Pay $692.57k)
• Ms. Teri Loxam, Chief Financial Officer (Age 49, Pay $633.03k)
• Mr. Lawrence J. Knopf, Gen. Counsel & Sec. (Age 59, Pay $474.45k)
• Dr. Oliver Rosen, Chief Medical Officer (Age 57, Pay $557.29k)
• Mr. Micah Zajic, Chief Bus. Officer (Age 40, Pay $288.65k)
• Dr. Robert S. Langer Jr., Co-Founder & Member of Scientific Advisory Board (Age 72)
• Dr. Howard Bernstein, Chief Scientific Officer (Age 64)
• Mr. David First, Chief People Officer (Age 57)

Who are some of SQZ Biotechnologies' key competitors?

Some companies that are related to SQZ Biotechnologies include Coherus BioSciences (CHRS), REGENXBIO (RGNX), Replimune Group (REPL), Ocugen (OCGN), iTeos Therapeutics (ITOS), Sangamo Therapeutics (SGMO), AlloVir (ALVR), Caribou Biosciences (CRBU), Humacyte (HUMA), Rubius Therapeutics (RUBY), Vaxcyte (PCVX), Century Therapeutics (IPSC), Vaxart (VXRT), Scholar Rock (SRRK) and BioAtla (BCAB).
View all of SQZ's competitors.

When did SQZ Biotechnologies IPO?

(SQZ) raised $75 million in an initial public offering on Friday, October 30th 2020. The company issued 4,400,000 shares at $16.00-$18.00 per share. BofA Securities and Stifel served as the underwriters for the IPO and BTIG was co-manager.

What is SQZ Biotechnologies' stock symbol?

SQZ Biotechnologies trades on the New York Stock Exchange (NYSE) under the ticker symbol "SQZ."

Who are SQZ Biotechnologies' major shareholders?

SQZ Biotechnologies' stock is owned by a number of retail and institutional investors. Top institutional investors include Temasek Holdings Private Ltd (9.83%), 683 Capital Management LLC (6.03%), BlackRock Inc. (4.46%), Maverick Capital Ltd. (3.77%), Geode Capital Management LLC (0.92%) and Bank of New York Mellon Corp (0.25%).

Which major investors are selling SQZ Biotechnologies stock?

SQZ stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, California State Teachers Retirement System, New York State Common Retirement Fund, and SG Americas Securities LLC.

Which major investors are buying SQZ Biotechnologies stock?

SQZ stock was purchased by a variety of institutional investors in the last quarter, including 683 Capital Management LLC, Temasek Holdings Private Ltd, Maverick Capital Ltd., BlackRock Inc., ACT Capital L.L.C., Geode Capital Management LLC, Two Sigma Investments LP, and Bank of New York Mellon Corp.

How do I buy shares of SQZ Biotechnologies?

Shares of SQZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SQZ Biotechnologies' stock price today?

One share of SQZ stock can currently be purchased for approximately $13.16.

How much money does SQZ Biotechnologies make?

SQZ Biotechnologies has a market capitalization of $369.36 million and generates $21 million in revenue each year.

How many employees does SQZ Biotechnologies have?

SQZ Biotechnologies employs 98 workers across the globe.

What is SQZ Biotechnologies' official website?

The official website for SQZ Biotechnologies is www.sqzbiotech.com.

Where are SQZ Biotechnologies' headquarters?

SQZ Biotechnologies is headquartered at 200 ARSENAL YARDS BLVD. STE. 210, WATERTOWN MA, 02472.

How can I contact SQZ Biotechnologies?

SQZ Biotechnologies' mailing address is 200 ARSENAL YARDS BLVD. STE. 210, WATERTOWN MA, 02472. The company can be reached via phone at 617-758-8672 or via email at [email protected].